ClinicalTrials.gg
CompletedNCT05468346Updated Apr 13, 2023

Study on the Body Mass Balance and Biotransformation of [14C]-HEC585

A Phase 1 interventional study of [14C]-HEC585 in Healthy Volunteer, sponsored by Sunshine Lake Pharma Co., Ltd.. Completed at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-13.

Sponsored by Sunshine Lake Pharma Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2022, 4 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

This is a single-centre, open-label, non-randomised, single-dose study in healthy male subjects designed to assess the mass balance and biotransformation of [14C]-HEC-585.

02

Conditions studied

  • Healthy Volunteer
03

In context

Lead sponsor

Sunshine Lake Pharma Co., Ltd. is the lead sponsor of 83 studies on the registry; 13 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy males, age: 18 to 45 years old (including the critical value);
  2. The body weight is not less than 50 kg, and the (BMI) is in the range of 19.0\~26.0 kg/m2 (including the critical value);
  3. Voluntarily participate in this trial, sign the form before the trial begins, and fully understand the trial content, process and possible risks;
  4. Subjects were able to communicate well with investigators and were able to complete the trial as specified in the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Comprehensive physical examination, vital signs, laboratory tests [blood routine, blood biochemistry, urine routine, coagulation function, fecal occult blood, thyroid function test (FT3, FT4, TSH)], 12-lead , X-chest X-ray (frontal) or chest CT, abdominal B-ultrasound (liver, gallbladder, pancreas, spleen and kidneys), new crown screening (nucleic acid + C-reactive protein) and other abnormal and examinations;
  2. Those who are positive for any one of surface antigen or E antigen, antibody, antibody and syphilis antibody;
  3. Those who have taken any drugs that inhibit or induce liver metabolism of drugs within 28 days before screening (see Appendix 1 for details);
  4. Use of any prescription or over-the-counter medicines, any vitamin products, health medicines or Chinese herbal medicines within 14 days prior to screening;
  5. Those who participated in any clinical trial and received intervention of experimental drugs or medical devices within 3 months before the screening period;
  6. Those who have been vaccinated within 1 month before screening or have a vaccination plan during the trial;
  7. Have any clinical history of serious diseases or diseases or conditions that the researchers believe may affect the results of the test, including but not limited to the circulatory system, endocrine system, nervous system, digestive system, urinary system or blood, immune, mental and metabolic diseases history;
  8. Those who have had heart failure, angina pectoris, myocardial infarction, clinically significant arrhythmia and other heart diseases in the past;
  9. Those who have undergone major surgery within 6 months before the screening period or the surgical incision is not completely healed. Major surgery includes but is not limited to any surgery with significant bleeding risk, prolonged general anesthesia, or incision or obvious traumatic injury ;
  10. Abdominal fistula, gastrointestinal perforation or abdominal abscess occurred within 6 months before screening;
  11. Have clinically significant bleeding symptoms or a clear bleeding tendency within 3 months before screening, such as gastrointestinal bleeding, hemorrhagic gastric ulcer;
  12. Hemorrhoids or perianal diseases with regular/hematochezia, abnormal gastrointestinal function such as irritable bowel syndrome and inflammatory bowel disease, which may affect drug absorption as judged by the researchers;
  13. People with allergies, including drug allergies or food allergies, or those who have special requirements for diet and cannot follow a unified diet;
  14. Habitual constipation or diarrhea;
  15. Binge drinking or frequent drinking within 6 months prior to the screening period, i.e. drinking more than 14 units of alcohol per week (1 unit = 285 mL of beer or 25 mL of 40% alcohol or 100 mL of wine) or alcohol during the screening period Breath test results ≥ 20 mg/dL;
  16. Those who smoked more than 5 cigarettes or habitually used nicotine-containing products in the first 3 months of the screening period, and were unable to quit during the trial;
  17. Drug abuse or use of soft drugs (such as marijuana) 3 months before the screening period or hard drugs (such as: cocaine, amphetamines, phencyclidine, etc.) 1 year before the screening period, or urine drugs during the screening period ( Drugs) screening test positive;
  18. Habitual drinking of grapefruit juice or excessive tea, coffee and/or caffeinated beverages and unable to quit during the trial period;
  19. Those with a history of fainting of needles or blood, difficult to collect blood or unable to tolerate venipuncture for blood collection;
  20. Workers who need to be exposed to radioactive conditions for a long time, or have significant radioactive exposure (≥2 chest/abdominal CT, or ≥3 other types of X-ray examinations) within 1 year before the test, or have participated in radiopharmaceutical labeling experimenter;
  21. Those who have fertility plans during the trial and within 12 months after the administration of the trial drug, or who do not agree that the subjects and their spouses should take strict measures during the trial and within 12 months after the administration of the trial drug (see details for details). Appendix 2);
  22. Those who have lost blood or donated blood up to 400 mL within 3 months before the screening period, or who have received blood transfusion, or who plan to donate blood within 3 months after the end of this trial;
  23. According to the judgment of the investigator, the subject has other factors that make it inappropriate to participate in this trial.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    [14C]-HEC585

    \[14C\]-HEC585,solid powder,200 mg/100 µCi,single dose,oral

    Drug: [14C]-HEC585

Interventions

  • Drug[14C]-HEC585

    Single Dose = Solution containing 200 mg/100 µCi \[14C\]-HEC585

06

What researchers measure

Primary outcomes

  1. Mass balance

    To determine the mass balance recovery of orally administered \[14C\]-HEC585

    Time frame: plasma up to 312 hours post dose, urine and fecal samples up to 504 hours post dose

Secondary outcomes

  1. Peak Plasma Concentration (Cmax) of HEC-585 and its major metabolites

    Analyze the Peak Plasma Concentration (Cmax) of HEC-585 and its major metabolites (if applicable) to obtain the corresponding pharmacokinetic parameters;

    Time frame: 312 hours

  2. Area under the plasma concentration versus time curve (AUC) of HEC-585 and its major metabolites

    Analyze the Area under the plasma concentration versus time curve (AUC) of HEC-585 and its major metabolites (if applicable) to obtain the corresponding pharmacokinetic parameters;

    Time frame: 312 hours

  3. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    To investigate the safety and tolerability of HEC585 by assessment of Incidence of Treatment-Emergent Adverse Events following administration of of oral dose of 200 mg/100 µCi\[14C\]-HEC-585

    Time frame: 504 hours

07

Study locations

1 site
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215006, China
08

References and documents

Publications

  • Hutchinson J, Fogarty A, Hubbard R, McKeever T. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J. 2015 Sep;46(3):795-806. doi: 10.1183/09031936.00185114. Epub 2015 May 14. PubMed 25976683 ↗
  • Olson AL, Gifford AH, Inase N, Fernandez Perez ER, Suda T. The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype. Eur Respir Rev. 2018 Dec 21;27(150):180077. doi: 10.1183/16000617.0077-2018. Print 2018 Dec 31. PubMed 30578336 ↗
  • Richeldi L, Rubin AS, Avdeev S, Udwadia ZF, Xu ZJ. Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China. BMC Med. 2015 Sep 24;13:237. doi: 10.1186/s12916-015-0495-0. Erratum In: BMC Med. 2021 Sep 5;19(1):220. doi: 10.1186/s12916-021-02111-4. PubMed 26399999 ↗
  • Ingegnoli F, Ughi N, Mihai C. Update on the epidemiology, risk factors, and disease outcomes of systemic sclerosis. Best Pract Res Clin Rheumatol. 2018 Apr;32(2):223-240. doi: 10.1016/j.berh.2018.08.005. Epub 2018 Sep 14. PubMed 30527428 ↗
  • Hoffmann M, Kasserra C, Reyes J, Schafer P, Kosek J, Capone L, Parton A, Kim-Kang H, Surapaneni S, Kumar G. Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration. Cancer Chemother Pharmacol. 2013 Feb;71(2):489-501. doi: 10.1007/s00280-012-2040-6. Epub 2012 Dec 1. PubMed 23203815 ↗
  • Hoffmann M, Kumar G, Schafer P, Cedzik D, Capone L, Fong KL, Gu Z, Heller D, Feng H, Surapaneni S, Laskin O, Wu A. Disposition, metabolism and mass balance of [(14)C]apremilast following oral administration. Xenobiotica. 2011 Dec;41(12):1063-75. doi: 10.3109/00498254.2011.604745. Epub 2011 Aug 23. PubMed 21859393 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2022 to primary completion in Aug 2022, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2022
First posted
Jul 21, 2022
StartActual
Jul 26, 2022
Primary completionActual
Aug 14, 2022
CompletionActual
Aug 29, 2022
Last update
Apr 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05468346
Responsible party
Sponsor
First posted
Jul 21, 2022
Start date
Jul 26, 2022
Primary completion
Aug 14, 2022
Completion
Aug 29, 2022
Last update
Apr 13, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion